A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Incyte Corporation
Incyte Corporation
Herlev Hospital
Sumitomo Pharma America, Inc.
Herlev Hospital
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.